Introduction: The efficacy of cyclosporine A (CsA) in the treatment of idiopathic membranous nephropathy (IMN) is unclear. This meta-analysis was conducted to assess the efficacy and the safety of CsA in the treatment of IMN in Asians. Methods: We searched the Pubmed, China Biomedical Database, CNKI, Wanfang Data, VIP, and EMBASE (November 30, 2018) systematically to identify the appropriate randomized controlled trials (RCTs) reporting the efficacy and the safety of CsA and glucocorticoid (GC) treatment vs other immunosuppressants and GC on patients with IMN in Asian populations. Results: The CsA treated group entered complete remission (CR) faster (3 months) than a cyclophosphamide (CTX) group. While the CsA group lower inefficacy rates and higher total remission (TR, CR, or partial remission) than the CTX group in the total treatment (3 months, 6 months, and 12 months), it had a higher relapse rate. As for the CsA group vs the tacrolimus (TAC) group, the TAC had a significant effect in increasing the CR and the TR, with decreased no remission. With the therapeutic regimens of CsA+GC vs CTX+GC, the CsA exhibited better efficacy in lowering the proteinuria levels only at 12 months, not at 3 months or 6 months. Severe events like leucopenia, hemorrhagic cystitis, and alopecia were observed in the CTX group. Gingival hyperplasia, hirsutism, and elevated blood pressure were reported only in the CsA group. Gastrointestinal syndrome, liver function lesion, happened more frequently in the CTX group, and elevated uric acid was more common in the CsA group. Conclusions: In brief, the CsA has better efficacy than the CTX group in the Asian population, with mild adverse effects but higher relapse rates in short-term treatment.
Introduction
Membranous nephropathy (MN) is the most common pathology in adults with nephrotic syndrome. Idiopathic membranous nephropathy (IMN), which consists of more than 20% of MN, is diagnosed when patients have primary MN without a secondary cause such as hepatitis B related nephritis, lupus nephritis, or malignancy, etc. 1, 2 Whether to treat IMN has been in debate for decades due to the observation that more than 20% of the patients can achieve spontaneous remission without immunosuppressive treatments. [3] [4] [5] These phenomena are more frequent in cases with lower baseline proteinuria. Some untreated IMN patients, especially young patients (<50 years old) with proteinuria <4 g/L, stable renal function at 6 months and
Inclusion and exclusion criteria Inclusion criteria
The inclusion criteria for the study were as follows: (1) 
Outcome measures
Complete remission (CR), partial remission, invalid remission, total remission (TR; CR or partial remission), serum albumin (g/L), 24 hr-proteinuria levels (g), serum creatinine (μmol/L), serum triacylglycerol (nmol/L), serum cholesterol (mmol/L), white blood cell counts and adverse events were used as outcome measures.
Data collection
Two researchers screened the literature (either to read the titles and abstracts or contents) to find appropriate passages according to the designed inclusion criteria and exclusion criteria. At the same time, we organized the group discussion to deal with debatable articles. In this way, we filtered irrelevant studies.
Data analysis and statistical method
To compare and analyze the efficacy and the safety of CsA, we used Review Manager Version 5.3 software to calculate clinical indicators and adverse events of patients with diverse medication treatments. A random effects model was applied to assess data when the P-value of the heterogeneity test was <0.1. Other data were assessed by a fixed model. The weighted mean differences were used to pool the continuous data, and binary data were expressed using the odds ratio (OR). 95% confidence intervals (CIs) were also calculated. χ
Results

Search results
This meta-analysis included a total of 22 randomized and comparative studies in Asian populations (involving 1,366 patients, with CsA and IMN (Table 1) . Sixteen studies [17] [18] [19] [20] [21] [22] [23] [25] [26] [27] [28] [29] [30] [32] [33] [34] reported effects of CsA plus glucocorticoid (GC) vs CTX plus GC. Three studies 24, 31, 35 reported comparisons among CsA plus GC, CTX plus GC, and mycophenolate mofetil (MMF) plus GC. Three studies [36] [37] [38] compared tacrolimus (TAC) with the CsA.
CR (complete remission)
Seventeen studies [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [30] [31] [32] [33] [34] assessed the effects of CsA+GC vs CTX+GC on IMN, and the CR rate was calculated. The CR rate in the CsA group was significantly higher when compared with that in the CTX group at 3 months (OR=2.07, 95% CI: 1.30-3.29; P=0.002; Figure 1 and Table 2) . 17, 19, 23, [25] [26] [27] [28] 33, 34 While at 6 months, 17, 19, 23, [26] [27] [28] 30, 33 (OR =1.46, 95% CI:0.99-2.16, P=0.06; Figure 1 and Table 2 ) and 12 months [17] [18] [19] [20] [21] [22] [23] [24] 27, 28, [32] [33] [34] (OR=1.18,95% CI: 0.90-1.55, P=0.22; Figure 1 and Table 2 ), this advantage was not present. Three studies 24, 31, 35 assessed the CR rate of CsA+GC vs MMF+GC. The CsA group had similar efficacy to the MMF group (OR=0.92,95%CI: 0.41-2.05, P=0.83; Table 2 ). Another three studies 24, [36] [37] [38] compared CsA+GC with the TAC+GC. The CsA group had lower CR rate when compared with the TAC group (OR=0.42, 95%CI: 0.21-0.85, P=0.02; Table 2 ).
NR (no remission)
Seventeen studies [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [30] [31] [32] [33] [34] were included in the comparison of CsA+GC vs CTX+GC. The NR rate of the CsA +GC group was less than the CTX+GC group at 3 months 17, 19, 23, [25] [26] [27] [28] 33, 34 (OR=0.52, 95%CI: 0.36-0.74, P=0.0004; Table 2 ), 6 months 17, 19, 23, [26] [27] [28] 30, 33 (OR=0.62, 95% CI:0.41-0.93, P=0.02; Table 2 ) and 12 months [17] [18] [19] [20] [21] [22] [23] [24] 27, 28, [32] [33] [34] (OR=0.51, 95% CI:0.36-0.73, P=0.0002; Table 2 ).
Three studies 24, 31, 35 compared CsA+GC vs MMF+GC.
The NR rate of the MMF group did not differ from the CsA group (OR=0.55, 95%CI:0.22-1.36, P=0.20; Table 2 ). Three studies 24, [36] [37] [38] calculated the NR rate of CsA +GC vs TAC+GC. Compared with the CsA group, TAC presented a decreased NR rate (OR=3.27, 95% CI:1.40-7.64, P=0.006; Table 2 ).
TR (total remission)
Seventeen studies [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [30] [31] [32] [33] [34] Figure 2 and Table 2 ) and 12 months [17] [18] [19] [20] [21] [22] [23] [24] 27, 28, [32] [33] [34] (P=0.0006, OR=1.81, 95% CI:1.29-2.53; Figure 2 and Table 2 ). Three studies 24, 31, 35 compared CsA+GC vs MMF+GC.
Compared with the MMF group, we found no significant difference in the TR rate of the CsA group (P=0.20, OR=1.82, 95% CI: 0.73-4.49; Table 2 ). Three included studies 24, [36] [37] [38] Table 2 ).
Proteinuria
In comparing CsA+GC vs CTX+GC, 11 studies concluded that IMN patients with CsA treatment presented with decreased proteinuria at 12 months 17, [19] [20] [21] 27, 28, 32, 34 (P=0.02), with a pooled mean difference of −0.66 (95%CI: −1.24, −0.08; Figure 3 and Table 2 ), but no significant difference at 3 months 17, 19, [25] [26] [27] [28] (P=0.11, OR=−0.35, 95%CI:
−0.78,0.08; Figure 3 and Table 2 ), or 6 months 17, 19, [26] [27] [28] 30 (P=0.96, OR=−0.01, 95%CI: −0.41 to 0.39; Figure 3 and Table 2 ). Two studies 36, 37 comparing CsA+GC with TAC+GC reported no differences in proteinuria (P=0.06, OR=0.36, 95%CI: −0.01 to 0.73; Table 2 ).
Serum albumin
In comparing CsA+GC vs CTX+GC, 17, 19, [25] [26] [27] [28] there were no differences in serum albumin at 3 months (P=0.48, OR=0.16, 95%CI:-0.27,0.59; Figure 4 and Table 2 ). At 6 months 17, 19, [26] [27] [28] 30 and 12 months, 17, [19] [20] [21] 27, 28, 32, 34 the CsA group exhibited higher serum albumin levels (P=0.002 at 6 months, P=0.03 at 12 months; Figure 4 and Table 2 ). The pooled mean differences were 0. CsA+GC vs CTX+GC For patients in the CTX+GC group, they received oral CTX (1 g per month) for 6 months. And then the treatment will be adjusted to once every 3 months. The accumulating dose is about 6-8 g. CTX+GC group received oral prednisone at a dose of 0.6-1.0 mg/kg per day. After 2-3 months, the dose would reduce gradually.
The CsA+GC group received oral prednisone at a dose of 0.15-0.5 mg/kg per day. After 3 months, the dose would reduce gradually. The CsA+GC group received oral CsA (1.0-1.5 mg/kg per day) divided into two times. And then we adjusted the medication to maintain blood concentration within 120-150 ng/mL. The drug dosage will be adjusted according to the patients' clinical effect and their blood concentration. After the treatment of 2-3 months, we would increase the dose of medication appropriately to patients who did not react to the drug. The dose is up to divided into two times. The blood concentration was monitored after 1 week, 2 weeks, and every month. And then we adjusted the medication to maintain blood concentration within 100-150 ng/mL. If the patients' creatinine clearance elevates more than 50% of their initial levels, then the CsA will be reduced to half of the dose. With this method, patients whose creatinine clearance still elevated would stop taking the CsA. After 3 months, if the patients 24 hrs proteinuria<1.0 g, the daily dose of CsA was tapered to a maintenance dose of 1.5-2.0 mg/kg per day. The CsA +GC group received oral prednisone at a dose of 0.5 mg/kg per day. After 8 weeks, the dose would reduce gradually. For patients in the CTX+GC group, CTX initiated at a dose of 1 g once per month, dissolved in intravenous infusion in 250 mL saline for 6 months. The accumulating dose is 6 g. The CTX+GC group received oral prednisone at a dose of 1 mg/kg per day (The maximum dose is 500 mg). After 8 weeks, the dose would reduce gradually. Both groups were treated for 6 months. 47 patients with IMN proven by renal biopsy, were included.
They are grouped into two groups randomly, 24 Prednisolone was maintained at a minimum of 5 mg/day during the study period. Concurrent treatment was not standardized; however, blood pressure and proteinuria were primarily treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Statins were used to decrease serum cholesterol levels. In the MMF group, oral MMF was added to corticosteroids. The MMF treatment regimen consisted of 500 mg twice daily in patients weighing less than 50 kg, or 750-1,000 mg twice daily in patients weighing more than 50 kg. The dose of MMF was adjusted in a range of 500-1,000 mg twice daily based on laboratory findings, at the discretion of the attending physician. The dose of MMF was reduced by 25-33% of the previous dose when a patient had moderate to severe diarrhea. MMF was withheld when the WBC count was less than 4,000/mm 3 or the patient had intolerable gastrointestinal symptoms, and was restarted at a 50% dose at least 2 weeks after recovery. MMF was discontinued when the patient showed severe adverse events, more than doubled values in liver function tests, newly developed malignancy, or increased serum creatinine level by over 50%. In the CsA group, oral CsA was added to corticosteroids. CsA was started at a dose of 4 mg/kg and the dose was adjusted to maintain a 100±50 ng/mL trough blood level. The trough level of CsA was not an absolute target and the dose could be adjusted at the physician's discretion. The dose was decreased in cases in which serum CsA level ≥250 ng/mL, there was an increase in serum creatinine level of more than 0.3 mg/dL compared to baseline, elevated serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level, or increased serum bilirubin level ≥2 mg/dL. CsA was discontinued when serum creatinine level did not improve 4 weeks after the dose was reduced in cases of increased serum creatinine ≥30% over baseline. CsA was also discontinued when the patient had severe adverse events or uncontrolled high blood pressure despite the use of three or more anti-hypertensive drugs at maximally tolerated doses.
Patients with biopsy-proven IMN were assessed for eligibility for this study at multiple centers in the Republic of Korea. We also included patients who underwent a biopsy within the preceding 12 months, experienced worsening proteinuria, and exhibited deteriorating renal function, but satisfied the following inclusion criteria. Patients who were ≥18 years old were enrolled in this study if they had proteinuria >8 g/day. Patients with proteinuria <8 g/day were also enrolled if they met three or more of the following criteria: (1) d) in the morning and evening. After 3 weeks, the physician would adjust its dosage according to patients' blood concentrations of FK506 to maintain a stable dose of 5-10 ng/ mL for 6 months. The dose would be reduced gradually after 6 months of treatment to maintain their blood concentration within 2-5 ng/mL.
The initial dose of oral prednisolone is 1 mg/(kg.d). After 8-12 weeks of treatment, the original dose is reduced by 10% to 20 mg/d, and reached the minimal dose of 10 mg/d after 6 months. If the patient's serum creatinine levels elevate more than 30% of the baseline value or the blood drug concentration exceeds 10 ng/mL, the TAC dose would be reduced. For patients with hyperglycemia, we adjust their dose or provide them with hypoglycemic agents. Control group: CsA combined with GC treatment: the initial dose of oral CsA dose is 5 mg/(kg.d) in the morning and evening. After 3 months of treatment, the dose will be reduced to 1-3 mg/(kg.d). The blood concentration should be measured during the treatment and maintained at 250-350 ng/mL. Prednisolone usage is consistent with the study group.
42 patients were treated with ACEI, ARB, anticoagulation, Statins, and diuretic drug, either to control high blood pressure, lower their proteinuria levels or lower their lipid levels.
42 patients with IMN were randomly divided into study group and control group, with 21 cases in each group. The study group (median age at study entry, 67.23±13.92 (range 54-78) years) consisted of 13 males and 8 females. The control group (median age at study entry, 68.02±10.57 (range 52-80) years) includes 12 males and 9 females.
Significant remission, remission, NR, significant remission rate, remission rate, NR rate, TR rate, 24 hr-proteinuria levels, serum albumin, endogenous creatinine clearance, serum creatinine, serum triacylglycerol, serum cholesterol.
Hyperglycemia, nephrotoxicity.
(Continued) (2) patients with HIV, heart failure, chronic hepatitis B virusassociated nephritis, chronic hepatitis C virus-associated nephritis, elevated liver enzyme detection value (elevated more than 2 times than normal value), diabetes mellitus diseases and other kidney diseases. (3) (Continued) Two studies 36, 37 compared CsA+GC vs TAC+GC. The
CsA had lower levels of serum albumin (P=0.03, MD= −1.17, 95% CI: −2.23, −0.12; Table 2 ).
Serum creatinine
In comparing CsA+GC vs CTX+GC, serum creatinine levels at 3 months 17, 19, [25] [26] [27] [28] 
Serum cholesterol
In comparing CsA+GC vs CTX+GC, serum cholesterol of the CsA group at 3 months 17,27 (P=0.04, MD=−0.49, 95% Table 2 ).
Serum triacylglycerol
In comparing CsA+GC vs CTX+GC, four studies 21, 27, 32, 34 assessed serum triacylglycerol at 12 months. CsA was consistent in its effects (P=0.0006 at 12 months; Table  2 ). Its pooled mean difference was as follows: −0.96 (95% CI:-1.50, -0.41; Table 2 ) at 12 months. The comparison of CsA+GC vs TAC+GC in two studies 36, 37 indicated that the TAC+GC group had lower serum triacylglycerol levels (P=0.03, MD=1.01, 95% CI:0.11 to 1.92; Table 2 ).
Other clinical indicators of CsA+GC vs CTX+GC
Comparison of CsA+GC vs CTX+GC, revealed difference in alanine aminotransferase (ALT) at 3 months (P=0.88, Table 2) . 17, 19, 20, 28 However, four studies 17, 20, 32, 34 indicated that white blood cell levels were lower with CTX treatment (P<0.00001, MD=1.31,95%CI: 1.04 -1.58; Table 2 ) at 12 months. Two studies 21, 30 reported no difference in urea nitrogen (P=0.99, MD=−0.00, 95% CI: −0.38 to 0.38; Table 2 ).
Adverse events
In comparing CsA+GC vs CTX+GC, the CsA group had more hirsutism 17, 19, 22, 27, 29, 30, 34 17, 18, 20, 22, [25] [26] [27] 29 (P=0.0002, OR=7.10, 95%CI:2.50, 20.14; Table 3) .
Gastrointestinal syndrome 19, 22, [25] [26] [27] 30 (P<0.00001, OR=0.05, 95%CI=0.02,0.17; Table 3 ), hemorrhagic Table 3 ).
Discussion
In the current meta-analysis, comparison of the CsA vs the CTX, even though CsA had more rapid effects on CR compared to CTX at 3 months, there were no differences in CR at 6 months or 12 months. While CsA had lower inefficacy rates and a higher TR rate than the CTX group across the total treatment period (3 months, 6 months, and 12 months), it also had a higher relapse rate. There were no differences in CR, NR, or TR rates between CsA and MMF. As for the CsA compared to TAC, TAC had significantly higher CR and TR rates, and decreased NR. The differences in the clinical index of the CsA group vs the CTX group are as follows: CsA has greater efficacy in lowering proteinuria levels only at 12 months, not at 3 or 6 months, Similar patterns were observed with increased serum protein levels and decreased serum cholesterol levels, which only differed in the later periods (6 and 12 months) but not at 3 months. White blood cells count at 12 months with CTX was significantly lower. CsA tended to be more effective in decreasing serum triacylglycerol. There were no differences in other clinical indicators, such as serum creatinine levels and the ALT, and urea nitrogen.
In comparing CsA+GC vs TAC+GC, TAC improved serum protein levels as well as reduced serum triacylglycerol compared to CsA. There were no differences in proteinuria, serum creatinine, or the serum cholesterol levels.
Adverse event rates also differed between CsA and CTX treated groups. Leucopenia, hemorrhagic cystitis, and alopecia were only observed in the CTX group. Gingival hyperplasia, hirsutism, elevated blood pressure, and elevated blood creatinine were only reported with CsA treatment. All of these adverse events manifested apparent diversity, except the elevated blood creatinine. Rates of other adverse events, including blood creatinine and tremor, were not significantly different. However, gastrointestinal syndrome, liver function lesion, was observed more often in the CTX group. Elevated uric acid levels were more common with CsA. To conclude, patients treated with CTX were more likely to have severe side effects compared to the CsA group.
Overall, CsA had better efficacy than CTX, with milder adverse effects but a higher relapse rate with short-term treatment. There were no significant differences between CsA and MMF in NR, CR, or TR rates. Although the TAC group had higher TR and CR, the NR rate was less than the CsA group.
Previous, meta-analyses have assessed the effects of CsA in treating IMN. Qiu et al, 39 calculated the TR and observed that the CsA took effect more quickly than CTX, but this was confined to the first 6 months of treatment in IMN patients (eight studies). However, there were no increased effects of CsA on TR rate (six studies), serum albumin or proteinuria at 12 months. Ren et al, 40 also performed a meta-analysis and concluded that CsA (six RCTs) was not superior to CTX in therapeutic effects (including CR and PR rates), when compared with nonimmunosuppressive treatment. Xie et al, 41 reported that
CsA had no effect improvement in CR rate, but better responsiveness by pooling two included studies (116 patients). In the current meta-analysis, we assessed 16 RCTs (1,094 patients) and found that CsA had lower inefficacy rates and higher TR rates when compared with CTX. CsA also had enhanced long-term efficacy in elevating serum protein levels and lowering proteinuria levels (at 12 months), similar to studies of Ren et al. 40 Qiu et al, 39 observed that CsA patients were more likely to relapse in comparison with CTX or TAC, and our study reported a higher relapse rate with CsA+GC compared to CTX+GC. Qiu et al, 39 also indicated a tendency for differences in adverse events (more severe adverse events like leukopenia, alopecia and liver damage with CTX, other events like hirsutism, gingival hyperplasia, worsening hypertension, and hyperuricemia occurred more often with CsA). Compared with the above meta-analyses, our metaanalysis included a greater number of RCTs to assess the safety and efficacy of CsA, which enhanced the strength of our conclusions. This meta-analysis was the first to compare TAC with CsA in patients with IMN. We carefully assessed longitudinal effects, and provided greater details on adverse events.
However, there was some limitations in this meta-analysis. The quality of some of the included studies was low, and some sample sizes were small. The sample sizes of some specific comparisons for assessing adverse events were small, making it difficult to detect differences.
CsA has recently attracted the attention of a wide range of researchers', and results of clinical trials of CsA suggest that it could replace CTX as the primary medication for treating IMN. Our study summarized the existing randomized clinical trial data and calculated whether CsA performed better than CTX, TAC, and MMF in IMN in Asian populations. In conclusion, CsA group has the potential to replace CTX, but nephrotoxicity should be carefully considered. Additional studies of the efficacy and safety of other medications such as MMF, TAC, and AZA are needed.
